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Technological and scientiﬁc innovations over the last decade have greatly contributed to improved diagnostics, predictive models,
and prognosis among cancers aﬀecting women. In fact, an explosion of information in these areas has almost assured future
generations that outcomes in cancer will continue to improve. Herein we discuss the current status of breast, cervical, and ovarian
cancers as it relates to screening, disease diagnosis, and treatment options.Among thediﬀerences in these cancers, it is strikingthat
breastcancerhasmultiplepredictivetestsbasedupontumorbiomarkersandsophisticated,individualizedoptionsforprescription
therapeutics while ovarian cancer lacks these tools. In addition, cervical cancer leads the way in innovative, cancer-preventative
vaccines and multiple screening options to prevent disease progression. For each of these malignancies, emerging proteomic
technologies based upon mass spectrometry, stable isotope labeling with amino acids, high-throughput ELISA, tissue or protein
microarray techniques, and click chemistry in the pursuit of activity-based proﬁling can pioneer the next generation of discovery.
We will discuss six of the latest techniques to understand proteomics in cancer and highlight research utilizing these techniques
with the goal of improvement in the management of women’s cancers.
1. Risk of Women’s Cancers
The likelihood of developing cancer and the speciﬁc type
of cancer vary tremendously during a woman’s lifetime
(Table 1). Among women in the USA who are between 40–
79 years of age, cancer is the leading cause of mortality.
This number decreases substantially for those of 80 years and
older after which cancer is usurped by heart diseases for the
top morbid distinction. In actuality, it is this group of 80
years and older that marginally places the ranking for heart
diseases above cancer as the overall leading cause of death in
the USA by approximately 53,000 people [1]. Since cancer is
far more likely to occur during the prime years of a woman’s
life, it therefore has an enormous impact on families, future
generations, business productivity, and loss to society.
Although men and women share this grim reality to-
gether, anatomical diﬀerences between the genders naturally
assign more cancer susceptibilities to women. Even with this
gender factor siding against women, they are remarkably
less likely than men to be diagnosed and succumb to cancer
by approximately 50,000 and 29,000 each year, respectively.
Some notable exceptions are lung, colon, and pancreatic
cancers, which aﬀect both groups equally [1]. Although
breast cancer can occur in both men and women, women
are far more likely to suﬀer a diagnosis or death as a result.
As an interesting inverse correlation, married men with
breast cancer are more likely to receive treatment and exhibit
reduced mortality [2], suggesting that women play a positive
supporting role for others with this malignancy. Women
are additionally susceptible to cancers of the ovary, vagina,2 International Journal of Proteomics
Table 1: Age-adjusted SEER incidence rates by age at diagnosis/death.
Statistical probability of diagnosis
Woman’s age <20 20–49 50–64 65–74 >75
Breast cancer — 72.5 270 416 414
Cervical cancer — 8.3 9.6 12 9.2
Colon cancer — 10 60 152 270
Corpus and uterine cancer — 9.4 66 95 73
Lung cancer — 6.7 76 265 328
Melanoma 0.79 16 29 41 46
Ovarian cancer 0.42 5.8 27.9 41 49
Pancreatic cancer — 1.4 14 45 79
Thyroid cancer 1.2 24 30 28 16
Vaginal cancer — — 1.2 2.5 3.3
Vulvar cancer — 0.92 3.5 7.1 13
Informational source: Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute, 2010.
“Incidence source: SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are
age-adjusted to the 2000 USA Std Population.”
— Statistics not displayed, <16 cases.
vulva, cervix, uterus, or endometrium lining the uterus.
They also have a far greater prevalence for thyroid cancer
(15.2 per 100,000 women) than men (5.2 per 100,000 men)
[3], which is particularly troubling given that some patients
report having no symptoms other than a lump on the throat.
The combined ﬁgures from the aforementioned women’s
cancers account for 25% of the total cancer mortality among
women in 2010 [1].
2. Breast Cancer ScreeningandDetection
Due to early detection, better diagnostics, and improved
treatment strategies, survival rates have vastly improved for
breast cancer patients within the past 30 years. In the 1970s,
the 5-year survival rate associated with breast cancer was
approximately 75%, and today it is over 90% [1]. Improved
outcomes are further highlighted by the fact that in the USA
today there are over 2.5 million women alive who have a
history of breast cancer [3], a triumph to successful scientiﬁc
and medical advancements.
Breast self-exams and clinical exams for palpable masses
along with mammograms are employed for the early screen-
ing of breast cancer. Most women who will be diagnosed
with ductal carcinoma in situ have tumors detected through
mammography [4], suggesting a prominent role for screen-
ing in the detection of this malignancy. The goalof the mam-
mogram is to detect small masses <1cm and calciﬁcations
[5]. Although lobular carcinoma in situ is not detectable by
mammography [6], it can be assessed through core needle or
excision biopsy. Lobular carcinoma in situ is unique because
these tumors are not typically discovered as palpable masses
and can present as mammographic calciﬁcation [7], which is
why routine mammography is so important. The detection
of calciﬁcation requires further analysis through additional
diagnostic imaging, magniﬁcation views, sonography, 6-
month followup exams, or biopsy [5].
Beforethe2009bombshellcontroversyandheatedpublic
response surrounding the USA Preventive Services Task-
Force initial updated recommendations for breast cancer-
screenings, women were recommended to have mammo-
grams starting at age 40, unless they had a high risk family
history and then the recommendation to start was at age
30. After the ensuing brouhaha, the following month the
Task Force “voted unanimously to update the language
of its recommendation ... mammography before the age
of 50 years should be an individual one and take patient
context into account, including the patient’s values regarding
speciﬁc beneﬁts and harms.” [8]. Further independent re-
commendations for the high risk group are for an additional
annual screening using MRI, which is more sensitive at-
detecting carcinomas than both sonography and mammo-
graphy, particularly in those with dense breasts. The
drawbacks to MRI include the reduced detection of calcif-
ications, the higher cost associated, and the increased time
required by the instrumentation [5].
Private online risk assessments exist for those seeking
no-cost answers for their health and curiosity. The National
Cancer Institute hosts a website for the Breast Cancer Risk
Assessment Tool (http://www.cancer.gov/bcrisktool/)w h i c h
estimates the risk for invasive cancer development. This
calculator only applies to women over 35 years old who
have not previously had a diagnosis of breast cancer. It asks
seven questions about a woman’s age, ﬁrst menstrual period,
ﬁrst childbirth, relatives, ethnicity (although it was designed
with data based on white and African American females),
and whether the woman has previously had a biopsy. Fair
warning for users: there is no “right” answer that produces a
0% risk, and the tool is based on an average of 12.6% lifetime
r i s kf r o m0t o9 0y e a r s .
3. Breast Cancer Biomarkers and Diagnostics
Breast cancer serves as a model for other cancers in that there
are a variety of biomarker-incorporating predictive tests
and therapeutic treatments to guide clinical decisions. Many
cancers have no early screening, detection, or prognosticInternational Journal of Proteomics 3
Table 2: Tests for risk assessment, treatment, or outcome in breast
cancer.
Breast cancer test Information obtained
Adjuvant! Online 10-year overall survival
Gail risk model Estimates the risk for
developing breast cancer
MammaPrint Relapse and metastasis
Mammostrat Clinical outcome and
overall survival
Oncotype DX Recurrence and adjuvant
therapy recommendation
St. Gallen Consensus Chemotherapy
recommendation
predictors available, and in that respect, breast cancer is
leading the way in innovation. The Nottingham Prognostic
Index is an early example of prognosis prediction among
breast cancer patients based on tumor size, stage of disease,
and tumor grade [9]. More sophisticated tests that are now
available are summarized in Table 2 and extensively reviewed
elsewhere [10]. Another recent test that was commercially
launched is Mammostrat, a ﬁve-biomarker, immunohis-
tochemical assay that measures CEACAM5, HTF9C, p53,
NDRG1, and SLC7A5 [11]. The major drawbacks are that
not every patient will fall exactly into the speciﬁc predictive
model, meaning that a small percentage may endure unnec-
essary overtreatment, and also that not all of these tests have
been exhaustively studied.
Clinical trials are ongoing to assess the accuracy of
predictive tests in breast cancer but many of these trials will
not be completed for several more years. For example, the
Trial Assigning IndividuaLized Options for Treatment (Rx),
or TAILORx, examines the reliability of Oncotype DX in
aidingindividualizedtreatmentoptions,assessingrecurrence
and predicting prognosis among 11,248 number of patients,
but will not be concluded until 2014 [12]. For patients
who are unwilling or unable to wait that long, these tests
may at least provide some directive guidance for clinical
conversations to seek the most appropriate individualized
treatment currently available in the medical arsenal.
The breast cancer prediction tests also vary in the pro-
teins, gene expression signatures, patient variables, clinical
histology,andotherbiomarkersortumorcharacteristicsthat
are incorporated into the model. One essential commonality
is the expression of hormonal or growth-factor-dimerizing
receptors within the tumor, and this still remains the
cornerstone for therapy in breast cancer. For instance,
whether a tumor is positive for the oestrogen receptor (ER),
progesterone receptor (PR), or the human epidermal growth
factor 2 receptor (HER2, also known as the ErbB2 receptor
or neu receptor) is tantamount for deﬁning the subtype of
breast cancer and assigning therapeutic intervention. Thus
far,thereareatleastﬁvemolecularlydeﬁnedsubtypes,which
can also categorize subtypes of breast cancers and these are
luminal-A, luminal-B, Her2, basal-like, and claudin-low; it
is unclear whether the controversial normal-like represents a
true molecular subtype or merely a contamination of breast
tumor specimens with normal mammary tissue [13–16].
Even with the newer classiﬁcations, hormone receptors
are still the most important factor regarding treatment. This
is because oestrogen is capable of driving the growth of
oestrogen-dependent tumors, and inhibiting this hormonal
factor is crucial to achieving a response to therapy. As
discussed below, there are layered approaches along with
many drugs that achieve this goal. Since protein receptors
arethusthefundamentalcriteriauponwhichotherdecisions
are based, it further highlights the critical roles proteins have
withinthetumorbiology,assigningtreatmentandpredicting
outcomes.
4. Breast Cancer PrescriptionTherapeutics
Following a medical diagnosis of breast cancer, the presence
of ER, PR, and HER2 is routinely tested and the tumor
is characterized to determine what the treatment regimen
will be. Breast cancer therapeutics are now so sophisticated
with targeted agents that this information is absolutely
critical to charting the course. In addition to the essential
knowledge of whether the patient’s tumor expresses ER, PR,
or HER2, the tumor (or tumors) size, lymph node stage and
histological grade of disease are critical and may determine
whether or not the patient will receive chemotherapy. It is
no longer the case that all women diagnosed with breast
cancer will undergo repeated cycles of chemotherapy to treat
their disease. Patients with a small breast tumor <1cm that
are diagnosed at an early-stage, and have not metastasized
are likely among this group since chemotherapy would
result in overtreatment and unnecessary side eﬀects [17].
Alternatively, schedules can vary greatly as neoadjuvant,
adjuvant, and dose-dense chemotherapy administrations are
all possible in this disease.
For breast tumors that are hormone-sensitive (ER- or
PR-positive), drugs that fall into the broad category of
oestrogen inhibitors are prescribed for 5 years or even
longer to reduce recurrence. Speciﬁcally, studies have shown
that 2 years of adjuvant tamoxifen reduces recurrence by
14% and mortality by 10%, while 5 years further reduces
these by 45% and 32%, respectively [18]. In premenopausal
women, ovarian ablation can occur through treatment with
luteinizing hormone-releasing agonists, radiation therapy, or
surgery [19]. Although there are now other drugs available
to mitigate oestrogen synthesis and signaling in both post-
menopausal and premenopausal women, the sequence of
ﬁrst-line treatment usually starts with tamoxifen, but could
also include toremifene or raloxifene. These are the antioe-
strogen drugs, which are also selective estrogen receptor
modulators. If endocrine resistance emerges, then aromatase
inhibitors like anastrozole, letrozole, exemestane, formestane
or fadrozole, that prevent the synthesis of oestrogen may
be used for second-line treatment and these are reviewed
elsewhere [20]. Fulvestrant, which binds to the ER, causes
the destruction of the receptor and is classiﬁed as a pure
antagonist. Due to this unique mechanism, it can be used as
either second- or third-line in the sequence of drug therapies
for hormone-sensitive breast tumors. Lastly, the progestin4 International Journal of Proteomics
megestrol acetate is used as third- or fourth-line therapy
for advanced breast cancer because of its antiestrogenic
and cytotoxic eﬀects [19]. Taken together, the number of
drugs and approaches to therapy provides many options for
therapeutic regimens lasting 5 years and even 10 years for
some patients.
Approximately 15–20% of breast cancer patients have
HER2-positive tumors [21], meaning their tumors overex-
press HER2, which dimerizes with epidermal growth factor
receptors and ampliﬁes aberrant signaling. On its own,
the HER2 receptor has no independent ligand. Among
these HER2-positive patients, the monoclonal antibody,
trastuzumab, or the small-molecule inhibitor, lapatinib, will
be prescribed to speciﬁcally target the HER2 receptor. Per-
tuzumab, another monoclonal antibody against the HER2
receptor, is still undergoing clinical trial testing. Thus far, in
doublet combinations with trastuzumab and the chemother-
apeuticagentdocetaxelthiscombinationmayhaveenhanced
eﬃcacy with the addition of pertuzumab [22].
Other groups of patients are categorized as triple-nega-
tive breast cancer, which is ER-, PR-, and HER2-negative and
a c c o u n t sf o ra p p r o x i m a t e l y1 5 %o ft u m o r s ,o ra d v a n c e d -
stage and metastatic breast tumors. These groups of patients
will require more chemotherapy than others for treatment.
Triple-negative tumors are insensitive to hormonal treat-
ments, yet investigational agents belonging to a class of
poly(ADP-ribose) polymerase or PARP inhibitors, including
iniparib, olaparib, and veliparib, may have some ability to
achieve response [23, 24]. Most patients with advanced
breast cancer that are given chemotherapy will receive the
“FAC” regimen, which stands for 5-ﬂuorouracil, dox-
orubicin, and cyclophosphamide. The “CMF” regimen,
which stands for cyclophosphamide, methotrexate, and 5-
ﬂuorouracil, is given to patients that are unable to receive
the anthracycline drug doxorubicin because of comorbid
medical conditions [25]. Other drugs that could be part
of a therapeutic regimen include paclitaxel, docetaxel, or
epirubicin [26].
5. CervicalCancer ScreeningandDetection
Although cervical cancer does not largely attribute to
mortality in the USA [1] due to advances in early screening
and detection, globally it is a major cause of death from
gynecologic cancer [27]. The human papilloma virus (HPV)
causes cervical cancer, and this virus is usually transmitted
through contact with squamous epithelial cells which are
susceptible to its infection. At least 100 or more genotypes of
HPV exist, and these are divided into two types, “high risk”
and “low risk,” reﬂecting the potential to induce invasive
cancer. It is the high risk types of HPV such as HPV-16 and
HPV-18thatare causallyinvolved in developing cervical[28]
and other anogenital cancers (Table 3)[ 29, 30]. Even though
genitalHPVinfectionisextremelycommonandoftencauses
no symptoms, some of the low risk viruses like HPV-6 and
HPV-11causerecurrentrespiratorypapillomatosisorgenital
warts and might be self-diagnosed, given the location [31].
The “Pap smear,” Pap test or Papanicolaou smear named
after Dr. George Papanicolaou the inventor, is a screening
Table 3: HPV types and associated diseases.
Disease HPV types
Genital warts 6, 11
Flat condyloma 6, 11,16,18,31
Cervical cancer
16, 18 (strong association)
31, 33, 35, 45, 51, 52, 56
(moderate association)
6, 11, 42, 43, 44 (weak
association)
Vulvar intraepithelial
neoplasia 16
Oral focal epithelial
hyperplasia 13, 32
Oral papillomas 6, 7, 11, 16, 32
Oropharyngeal cancer 16
Laryngeal papillomatosis 6, 11
Strategies for discovering
biomarkers
Proteomics
Glycomics Metabolomics
Genomics
Pharmacogenomics Transcriptomics
Lipidomics Epigenomics Systems biology
Interactomics
Personalized cancer medicine
Figure 1:Fromomics-basedsystemsbiologytopersonalizedcancer
medicine.
technique to detect early evidence of cervical cancer. The
Pap smear collects cells scrapped from the outer opening of
thecervixoftheuterusandthenexaminesprepsofthosecells
underneath a microscope to determine whether abnormali-
ties are present in the cervix. There is also a “HPV test” that
can be combined and tested simultaneously with the Pap
smear to conﬁrm the presence of the virus. Should abnor-
malities indeed be present, then a colposcopy is performed
to evaluate the area (Figure 1). The Pap smear is the best
example of a cancer screening program; however, sometimes
false-positive or false-negative results do happen, leading to
unnecessary followup or causing delay in the diagnosis and
treatment of precancer and cancer, respectively. Therefore,
alternative or complementary screening tools are needed to
overcome the limitations of Pap smear and produce a better
outcome.
6. CervicalCancer Biomarkersand Diagnostics
Thereareproteinbiomarkersthatcouldhaveutilityinassess-
ing disease risk, early detection, and prognosis in cervicalInternational Journal of Proteomics 5
cancer. For example, the HPV E6 and E7 oncogenes play an
essential role in HPV-induced carcinogenesis by interfering
with normal cellular events and are possible biomarkers for
earlydetectionofcervicalcancer.Studiesshowthatdetection
of E6/E7 mRNA expression could predict the risk of cervical
cancer better than HPV DNA testing [32] and currently the
commercially available mRNA-based assays (e.g., NucliSENS
EasyQ HPV Test and APTIMA HPV mRNA Assay). Arbor
Vita Corporation has developed a rapid diagnostic test, “AV
Avantage HPV E6 test” in collaboration with PATH (the
Program of Appropriate Technology in Health), a nonproﬁt
global health agency, with FDA approval targeted in 2013.
AV Avantage HPV E6 test uses a high-aﬃnity monoclonal
antibody for the detection of E6 oncoprotein from high risk
HPV-16, -18, and -45 responsible for approximately 90%
of cervical cancers. Small clinical pilot studies showed a
potential feasibility and clinical applicability of AV Avantage
HPV E6 Test [33], and further investigation is underway.
The tumor suppressor p16INK4A plays an important
role in regulating the cell cycle and is overexpressed in
the presence of the HPV E7 oncoprotein. Several studies
reported p16INK4A as a useful diagnostic marker for squa-
mous and glandular epithelial dysplasia in the uterine cervix
[34, 35] and a valuable surrogate marker for high risk and
malignant cervical lesions in the presence of HPV [36].
Furthermore, expression of p16INK4A appears to correlate
with the degree of cervical neoplasia [37, 38]. A recent
study showed that a p16INK4A immunocytochemical assay
has better speciﬁcity than HPV testing to predict underlying
high-grade dysplastic lesions [39]. Currently, clinical trials
areunderwaytoassessthediagnostic andprognostic valueof
p16INK4A expressioninatypicalglandularcellsandlow-grade
squamous intraepithelial lesions of the cervix.
Squamous cell carcinoma antigen (SCC-Ag) is a marker
ofsquamouscellcarcinomasinthecervix[40]andexpressed
in normal cervix epithelium with an increased expression
in dysplastic lesion and cervical squamous cell carcinoma.
SCC-Ag is not sensitive or speciﬁc enough for detection
of early-stage cervical cancer; however, pretreatment serum
SCC-Ag values serve as a strong, independent prognostic
factor [41]. Several studies have concluded that SCC-Ag is
useful for posttherapy surveillance monitoring of cervical
cancer [42] and is currently being used in some hospitals.
The persistent increase of serum SCC-Ag levels during and
after radiotherapy is associated with persistent or recurrent
disease[43],indicatingtheimportantimplicationofSCC-Ag
forfurtherdiagnosticworkupandclinicalmanagement[44].
Ki-67 is a nuclear protein that is expressed during all
active phases of the cell cycle, and its expression is used to
determine the cell proliferation status [30, 45]. In cervical
intraepithelial neoplasia (CIN), Ki-67 expression is increased
in the upper layers of cervical epithelium compared to nor-
mal cervices [30, 46, 47] .S e v e r a ls t u d i e sh a v ea l s os u g g e s t e d
that Ki-67 can be used as an independent prognostic marker
to identify women with high risk for progression and/or
recurrence of cervical squamous precancerous lesions [48].
The eukaryotic minichromosome maintenance (MCM)
protein family consists of six essential proteins (MCM2-
7), all of which are necessary for DNA replication [49, 50]
and are abundantly expressed through the cell cycle [51,
52]. While MCM protein staining is limited to the basal
proliferating layer and absent in diﬀerentiated cells, its
expression is signiﬁcantly increased in cervical glandular
and squamous dysplasia [53, 54], suggesting its potential as
a biomarker of cervical dysplasia. Studies have revealed a
strong correlation between the number of nuclei positive for
MCM2 and MCM5 at the surface of dysplastic epithelium
and the severity of dysplasia [53, 55]. MCM7 has also been
identiﬁed as a highly informative marker of cervical cancer.
Full thickness staining for MCM7 staining was observed in
high-grade cervical epithelial lesions and invasive cervical
carcinoma [55, 56].
Topoisomerase IIα ( T O P 2 A )f u n c t i o n sa sak e ye n z y m e
in DNA replication and cell cycle progression [57]. Increased
expression of TOP2A was observed in cervical disease and
cancer [58], and its expression is correlated with increased
risk of progression from CIN2 to CIN3 [59]. A novel reagent
that detects MCM2 and TOP2A is commercially available
(BDProExC)andisaproposedmarkerwiththepotentialfor
detecting high-grade squamous intraepithelial lesions in cer-
vical biopsy specimens [60]. Interestingly, the performance
of BD ProEx C as a complementary surrogate marker to
p16INK4A and Ki-67 showed improved diagnostic accuracy
[60], suggesting its potential clinical use. Currently, BD
ProEx C and other molecular markers are being investigated
to improve cervical cancer diagnosis.
7. Cervical Cancer PrescriptionTherapeutics
Currently, there are two HPV vaccines on the market, Gar-
dasil and Cervarix. The approval of these novel therapeutics
championed the ﬁrst bona-ﬁde cancer prevention drugs
approved by the FDA. Both vaccines protect against the
acquisition and infection of HPV-16 and -18, the types
of viruses responsible for approximately 70% of cervical
and other genital cancers [61]. Additionally, Gardasil also
protects against HPV-6 and -11 which cause approximately
90% of genital warts and potentially prevents precursors to
penile, vulvar, vaginal, and anal cancers [61]. The major
drawback of these vaccines is that they cover the most
commontypesofHPV,butnotall100-plusgenotypes.Thus,
vaccinated women would still need to have regular screening
tests routinely performed to ensure they were not at risk
for cervical cancer. In other words, the vaccines do oﬀer
a level of protection, but are not enough to eliminate all
risks of HPV infection. It is unclear whether infrequently
appearing HPV types will become more prominent among
thehumanpopulationasalong-termresultofthesevaccines.
Furthermore, without 100% compliance from the popula-
tion in supporting these somewhat controversial vaccines, it
is unclear how eﬀective they will be on reducing incidence
of cervical cancer, the costs of screening and detection, and
anxiety surrounding positive- or false-positive Pap smear
results.
Cervical cancer is staged by the Federation of Inter-
national Gynecology and Obstetrics (FIGO) system, which
begins at 0 and ends at IV. In advanced stages of disease,
like most other types of cancer, chemotherapy will be6 International Journal of Proteomics
administered to the patient to control the growth and spread
of tumors. If early abnormalities of the cervix are not
removed, these abnormalities or precancerous lesions could
develop into carcinoma in situ, low-grade or high-grade CIN
and then into cancer. For cervical cancer, stage I–III disease
will likely require combination regimens with cisplatin and
another agent, either 5-ﬂuorouracil, topotecan, paclitaxel,
vinorelbine, or irinotecan [26]. Radiation therapy may also
be part of the treatment plan. For patients with stage IV
disease, a barrage of chemotherapy available in the oncology
arsenal may be used.
8.OvarianCancerScreeningandDetection
An unfortunately and sometimes heart-wrenching clinical
reality is that no early screening or early diagnostic test exists
to indicate a woman has ovarian cancer. The Papanicolaou
test or “pap smear” will not detect ovarian cancer, and
even routine well woman exams have failed to detect
malignancy, much to the newly diagnosed patient’s distress
and frustration. One reason outcomes are generally poor is
that the majority of patients present with late-stage disease
due to very general symptoms that may persist for years and
could be attributed to other factors. For example, the most
frequent symptoms reported in the clinic include abdominal
bloating, pain or swelling, dyspepsia, urinary frequency and
signiﬁcant or unexpected weight change. Other symptoms
reported by patients include painful intercourse, a change in
bowel habits, backaches, and fatigue. Thus, these symptoms
might not elicit signiﬁcant attention from the patient until
the disease has spread and developed into a later stage,
causing the symptoms to be unbearable. This is the rationale
behind public education and awareness programs that have
adopted whisper campaigns to encourage women to notice
the combination or subtle changes among normal bodily
functions.Alternatively,apractitionercouldmisdiagnosethe
generalizable symptoms as more common maladies, such as
irritable bowel syndrome.
Most tumor staging systems use the convention that
spreading from the primary tumor describes a metastatic,
stage IV disease. This is not necessarily the system that has
evolved for ovarian cancer, which uses the FIGO system.
Ovarian cancer staging occurs during the surgery and is
basedonoperativeconclusionsobserved,wherebymalignant
cells can be found in peritoneal washings as early as stage Ic
and metastases to the uterus is categorized as stage IIa [62].
In addition, the fact that malignant cells shed and passively
move through the peritoneal cavity so early in malignancy
generates signiﬁcant challenges for treatment.
9.OvarianCancerBiomarkers andDiagnostics
Corresponding with the problem of unavailable diagnostics
for this malignancy, there is also a lack of biomarkers
due to the speciﬁcity requirement of this rare disease.
Many worthy ideas have not been able to achieve suﬃcient
levels of sensitivity and speciﬁcity in ovarian cancer, leaving
women without any reliable means of early detection. In
addition, there have been many problematic ovarian cancer
biomarkers that did not live up to the ground-breaking
status original perceived, which could not be validated upon
subsequent examination [63]. There are, however, plenty of
innovative biomarker ideas that have not yet been rigorously
examined in clinical trials [64, 65] to determine utility and at
least one older example of a classical discovery which is being
used in a new way.
This classical discovery surrounds CA-125, which is also
known as cancer or carbohydrate antigen 125, and may be
elevated when malignant disease is present. CA-125 is actu-
ally mucin 16, a carbohydrate glycoprotein that is expressed
and shed by the cells, but lacks speciﬁcity and sensitivity
to be used as a screening tool for ovarian cancer. The
originally discovery of CA-125 occurred when investigators
developed and tested OC125, a clone that produces an IgG1
murinemonoclonalimmunoglobulinthatreactedwith6of6
epithelial ovarian cancer cell lines and patient tissue [66]. At
the time, investigators were searching for an immunotherapy
and/or a unique tumor-associated antigen on the cell surface
for immunodetection; this discovery was the 125th attempt.
Although the novel discovery was found to be useless as
a treatment, CA-125 showed some ability as a biomarker.
The majority of ovarian cancers shed CA-125, which is
the basis for this association. In its currently use, patients
previously diagnosed with ovarian cancer will have blood
levels measured for CA-125 to indicate disease recurrence,
monitor disease progression, response to treatment, or
predict prognosis after treatment. In these situations it
is considered a generally reliable tool for clinicians, even
though small percentages of women with ovarian cancer
will not have signiﬁcantly elevated levels. Prior to surgical
debulking, ovarian cancer patients might have CA-125 that
exceeds 2000 units (some patients even exceed 10,000 units)
while most normal healthy women have levels of CA-125
<35 units in circulation. There are conditions unrelated to
ovarian cancers that cause a rise in CA-125, and this limits
theutilityofthemeasurement.Forexample,normalovarian,
pancreatic, and breast cells along with tissues lining the
abdomen and chest make and release low levels of CA-125.
In addition, diverticulitis, pelvic inﬂammatory disease and
pancreatitis are all examples of abdominal conditions that
increase CA-125 and are noncancerous.
A clinical trial recently assessed whether starting second-
line chemotherapy based on CA-125 level elevation, not
the appearance of symptoms, would aﬀect outcomes by
theoretically beginning treatment earlier with recurrent
disease. Surprisingly, the results failed to demonstrate an
increase in survival in the application of this idea [67]. Some
critics charged that not sorting patients based on computed
tomography scans could have aﬀected the results and that
guidelines for monitoring patients’ CA-125 levels should
not be changed based on this study [68]. Controversies
surrounding the use of nonperfect biomarkers are not only
applicable to CA-125; the PSA test has encountered similar
criticism [69].
What is the best utility of CA-125, and can it be used
in other ways to help provide clinical guidance for the early
detection of ovarian cancer? A prospective study performed
at the University of Texas MD Anderson Cancer CenterInternational Journal of Proteomics 7
sought to address this question by considering the change
in CA-125 over time. The clinical trial stratiﬁed women into
threegroupsoflow,mid,andhighrisk,baseduponabaseline
CA-125 reading, the current measurement, and the woman’s
age. Using the results from the calculated risk, women in
the high risk group received transvaginal sonography and
it was determined that ﬁve women indeed had early-stage
ovarian cancer [70, 71]. This suggests that CA-125 may have
a place in diagnosis when coupled with other diagnostic
technologies and/or biomarker tests. If such techniques like
transvaginal ultrasound coupled with biomarker detection
can enhance screening or diagnostics of ovarian cancer, then
ongoing clinical trials may elucidate this possibility. Recently
it was suggested that transvaginal ultrasound screening for
women at high risk of endometrial cancer could have a role
in patient management [72]. In this case, the screening is
designed to measure increasing endometrial thickness and
other abnormalities. In a large case-controlled study that
included more than 40,000 women, transvaginal ultrasound
demonstrated good sensitivity in postmenopausal women,
although the report of results stopped short of recommend-
ing population screening [72].
In 2009 the FDA approved the ﬁrst blood serum test,
OVA1, designed to assist determining whether a suspicious
pelvic mass is malignant ovarian cancer prior to a planned
surgery. The test is not intended for screening and cannot
be used alone. It is approved in combination with standard
surgical evaluations, which seems to reduce its usefulness;
however, the utility of OVA1 occurs in cases where other
clinical tests do not indicate malignancy when it is present.
OVA1 uses ﬁve immunoassays to derive an independent
score (0–10, indicating no risk to highest risk) based on
proprietary software called OvaCalc, and this score suggests
the likely risk of malignancy, but is not considered a
diagnosis of ovarian cancer. The ﬁve proteins that the assay
measures include apolipoprotein A-1, beta2-microglobulin,
transferrin, transthyretin, and CA-125 (http://www.ova-1
.com/)[ 73].
In 2010, an FDA-approved test for human epididymis
protein 4 (HE4), a secreted protease, became available for
monitoring recurrenceor progression of ovarian cancer. Pre-
viously, HE4 was touted as a biomarker for ovarian cancer;
furthermore, measurements of HE4 successfully detected
malignancywith 67% sensitivity and 96% speciﬁcity [74].To
enhance the monitoring capability of HE4, other assays that
measuremesothelinand/orCA-125arebeingexperimentally
tested and clinically evaluated to determine whether a
combinatorial test has clinical utility above HE4 alone,
particularly in suspect patients with a pelvic mass [75, 76].
When HE4 was combined with CA-125 and two other
biomarkers,thefour-panelsetwasabletodiagnoselate-stage
ovarian cancer with a sensitivity of 93% and speciﬁcity of
98% [65], suggesting the combination is superior to any one
biomarker alone.
10. OvarianCancer PrescriptionTherapeutics
Although adjuvant chemotherapeutics for ovarian cancer are
capable of reducing disease to undetectable levels in combi-
nation with surgical debulking, the therapeutic modalities
are not nearly as sophisticated as those of breast cancer.
In fact, the most impactful breakthrough for this disease
occurredinthelate1970swhencisplatinwasintroducedinto
clinical trials and received rapid FDA approval for this indi-
cation. At that time, several clinical studies using cisplatin
demonstrated its ability to increase response rates, relieve
symptoms from ovarian tumors, and improve survival [77–
79]. The next major breakthrough occurred in the early
1990s when paclitaxel or taxol, a product derived from bark
on the Paciﬁc yew tree, was FDA approved after clinical
studies suggesting activity against this malignancy [80, 81].
D u et ot h ef a v o r a b l es a f e t yp r o ﬁ l ea n de ﬃcacy of Taxol after
its initial discovery period, unprecedented demand caused
drug shortages and the National Cancer Institute established
plans to increase the drug’s supply through partnerships and
commercialization [82, 83].
Theculminationofthesediscoveriesleadtotheestablish-
ment of ﬁrst- and second-line chemotherapeutic regimens
forovariancancerusedtoday,theformerwhichissixcourses
of a platinum- and taxane-based combination [17]. For
women who are diagnosed with stage IIa or greater stages
of ovarian cancer, all of the following are possible in addition
tosurgicaldebulking:totalabdominalhysterectomy,bilateral
salpingo-oophorectomy, omentectomy, pelvic irradiation,
and systemic chemotherapy. The recommendation for sys-
temic chemotherapy is in contrast to the minority of women
who are diagnosed with stage Ia or Ib with grade 1 and 2
lesions where chemotherapy is not recommended [62].
Second-line chemotherapy largely depends on how the
patient responded to ﬁrst-line treatment. This is due to
the fact that the ﬁrst-line chemotherapy regimen may be
used again when the patient reappears in the clinic with
the same malignancy. For example, the categories include
platinum-sensitive, partially platinum-sensitive, platinum-
resistant, and platinum-refractory disease [17]w h i c hw i l l
guide whether cisplatin or carboplatin is administered. Since
the majority (approximately 75%) of ovarian cancer patients
will relapse, some with refractory disease, the establishment
of appropriate second-line therapy is critical. If a patient
is grouped into the platinum-refractory disease category,
then other agents like liposomal doxorubicin, topotecan,
gemcitabine, etoposide, or single-agent paclitaxel may be
administered [26]. Clinical trials are underway assessing the
response rate when administering bevacizumab or PARP
inhibitors in this malignancy.
11.New andEmergingProteomics
Techniques in Cancer Research including
PrognosticTechniques
In the postgenomic era, clinical proteomics strategy for deci-
phering and characterizing the diseased proteome network is
clearlybecominganextmajorchallengetobetterunderstand
the aberrant changes that cause cancer, predict a patient’s
risk of developing certain types of cancer, predict outcomes,
and guide treatment decisions. The recent advancement in
clinical proteomics technologies shows great promise for8 International Journal of Proteomics
improvementinallofthoseareas,eventuallyleadingtobetter
patient outcomes; however, studies applying proteomics
technologies to clinical applications have suggested there
are big challenges to overcome. Therefore, researchers are
increasingly interested in using a combination of proteomics
andother“OMICS”technologiesthathaveshowedfeasibility
in the clinical setting, but further evaluation and validation
is necessary (Figure 1).
AsmoreisdiscoveredaboutDNA,RNA,andsmallRNAs,
the latter which appears to be a constantly growing ﬁeld, it
is realized that the end point is a change in protein. Protein
changes caused by gain- or loss-of-function mechanisms via,
for example, protein-protein interaction or posttranslational
modiﬁcation may contribute to the etiology of cancer. Due
to the complexity of proteins as well as the dynamic nature
of the proteome in human body, traditional proteomic
approaches have been a diﬃcult task. For these reasons,
proteomics technology is being extensively explored and has
now become an emerging ﬁeld in cancer research. It is the
ﬁnal frontier of “OMICS” research, the missing puzzle piece.
P r o t eo m i cshasledan dwi llc o n ti n uet oleadusallt o war dthe
future of personalized cancer management. In this section
below, we will discuss emerging new proteomics strategies
and implications for cancer research.
12.ProteinAnalysisUsingMass Spectrometry
Mass spectrometry oﬀers a number of advantages for the
biochemical analysis of lipids [84, 85], nucleic acid frag-
ments, [86] and proteins, thus it has become a powerful and
indispensable tool for proteomic studies [87–89]. This inno-
vative and pioneering technique has taken protein analysis
to the next level, beyond the days when laboratories relied
on one- and two-dimensional gel electrophoresis capable of
resolving a few hundred proteins, which would then require
sequencing. Mass spectrometry is capable of resolving thou-
sands of proteins and thus allows scientists to quantitatively
probe the proteome, oncoproteome, or secretome on an
in-depth level that was previously impossible. On another
note, mass-spectrometry has revolutionized forensic science
through the analysis of hair ﬁbers, gunshot residues, and
chemical detection used in drug testing, arson investigations,
and explosives. Despite the recent technological advances
of mass-spectrometry, great challenges are still presented
in establishing high-resolution, accurate mass-spectrometry
methods for quantitative bioanalysis. Over the past several
years, many novel mass-spectrometry-based quantitative
proteomic methods have been developed for quantitative
analysis of relative diﬀerential changes in protein abundance.
13. StableIsotopeLabelingwithAminoAcidsin
CellCulture(SILAC)/Super-SILAC
Among the many formats of quantitative proteomics meth-
ods, stable isotope labeling with amino-acids in cell culture
(SILAC) has become a powerful and versatile tool [90].
The SILAC technique labels proteins with either natural
“light” or nonradioactive, stable isotope-containing “heavy”
amino-acids using the natural metabolic machinery of the
cell (typically 13C15
6 N2-Lys (8.0142 Da) and 13C14
6 N4-Arg
(10.00827 Da), resp.). When “light” and “heavy” amino-
acid-labeled cells are mixed, those cell populations remain
distinguishable by mass-spectrometry. Therefore, protein
abundances can be determined from the relative mass-
spectrometry signal intensities [91, 92].
UsesoftheSILACtechniqueincludestudying diﬀerential
protein expression and identifying biomarkers and drug
targets in pancreatic [93] and breast cancer [94, 95].
Bose and colleagues used the SILAC method to analyze
ErbB2/Her2 signal transduction pathways and the eﬀect of
a tyrosine kinase inhibitor, PD168393 [94]. This study led
totheidentiﬁcationofimportantphosphoproteinsincluding
many known Her2 and EGFR signaling proteins, as well
as previously unidentiﬁed Her2 signaling proteins, such as
Stat1, Dok1, and δ-catenin, providing valuable leads for
designing optimal future therapies in Her2-related breast
cancer. Another recent study used this method in breast
cancer cells treated with suberoylanilide hydroxamic acid
(Vorinostat), a histone deacetylase (HDAC) inhibitor, and
revealed changes in the expression of transcription factors,
regulators, chaperones, cell structure proteins and glycolytic
enzymes, further deﬁning the function of the HDAC
inhibitor in breast cancer [96]. These studies demonstrated
that the SILAC is a powerful method for investigating the
dynamics of protein abundance in signaling networks.
However, the limitation of this technology is that it
requires full metabolic labeling of the whole proteome; it
is, therefore, thought to be suitable only for analyzing cell
culture not human tissue or body ﬂuid samples [92]. Mann
and his colleagues have recently developed a “super-SILAC”
mixture, which combines ﬁve SILAC-labeled cell lines with
human carcinoma tissue, generating suﬃcient amounts of
isotopicallylabeledpeptidestoserveasinternalstandardsfor
mass-spectrometry-based analysis [92]. It seems that super-
SILAC has opened a new avenue in quantitative proteomics
and it may hold considerable promise for the future study of
the cancer proteome.
14.Matrix-AssistedLaser
DesorptionIonization-Imaging
Mass Spectrometry (MALDI-IMS)
Developments of matrix desorption and ionization tech-
niques such as matrix-assisted laser desorption ionization-
mass-spectrometry (MALDI-MS) [97, 98] and electrospray
ionization-mass-spectrometry (ESI-MS) [99]h a v ec l e a r l y
revolutionized protein science. These improvements oﬀer
higher accuracy and sensitivity of the protein mass measure-
ment. MALDI-imaging mass-spectrometry (MALDI-IMS)
is a new imaging method based on mass-spectrometry,
allowing the direct visualization of peptides, proteins, lipids,
and metabolites as well as other low mass small-molecules
on fresh frozen or ﬁxed paraﬃn-embedded tissue sections
[100].
The invention of MALDI-IMS was a major breakthrough
bymakingitpossibletostudythelocalizationandabundance
of molecules without multiple steps of sample preparation.International Journal of Proteomics 9
In addition, fresh frozen tissue samples are used in this assay.
Brieﬂy, matrix is uniformly applied to the tissue section,
which has already been mounted and sliced, and then the
scanning is carried out in raster fashion over thin tissue
sections. Each pixel contains information of a full mass
spectrum, thus, the molecular proﬁle of the proteomic
content of the tissue is available [101]. One very striking
ﬁnding resulting from this technology is that the aberrant
changes in protein expression within kidney tumors are
also detected in the normal tissue that surrounds the tumor
[102, 103].
Since MALDI-IMS can produce molecular protein sig-
natures of both healthy and diseased tissues, it has suc-
cessfully led to the identiﬁcation of diagnostic, prognostic,
and therapeutic protein biomarkers and produced a novel
classiﬁcation of diseases [104, 105]. Proteomic proﬁling
using MALDI-IMS has been applied to multiple types
of diseased tissues, including human nonsmall-cell lung
tumors [106], gliomas [104], prostate [107], breast [108],
and ovarian cancer [109]. In addition, molecular signatures
provided by MALDI-IMS applied to study of therapeu-
tic response to HER2 receptor inhibitors OSI-774 and
trastuzumab/Herceptin [110], tumor grading, and predic-
tionofpatientsurvival[100].Recentdatareportedtheability
of a proteomic signature to accurately deﬁne HER2-positive
fromHER2-negativetissues[108].Collectively,MALDI-IMS
using frozen or ﬁxed paraﬃn-embedded tissues has shown
unique advantages and could provide a better understanding
of cancer onset and progression and a new strategy for
biomarker discovery.
15.Activity-BasedProteinProﬁling(ABPP)
Activity-based protein proﬁling (ABPP), a powerful resource
for functional proteomics, was ﬁrst invented by Dr. James
C. Powers in the early 1990s and adopted and developed
by Dr. Benjamin F. Cravatt III and other researchers to
identify speciﬁc activities in proteome samples [111]. ABPP
employs active site-directed, small-molecule-based covalent
probes to directly determine the functional state of large
numbers of enzymes in native biological systems [112].
The probes for this assay, called activity-based probes, must
have both a reactive group to bind in enzyme activation
sites and a reporter tag, such as a ﬂuorophore, that is
required for their detection [113]. As examples of this,
activity-based probes have been successfully developed for
many enzyme classes, including histone deacetylases [114,
115], caspases [116], cytochrome P450s [117], metallo-
proteinases [118], proteases [119, 120], kinases [121–123],
phosphatases [124], glycosidases [125], and oxidoreductases
[126–128].
For in situ or in vivo labeling, the activity-based probes
are altered through substituting the reporter tag with a
handle, such as an alkyne or azide for use with the Huisgen
1,3-dipolar cycloaddition (click chemistry) [129, 130]. In
vitro activity-based ﬂuorescent probes can provide the
dynamics of enzyme activation over time, with the caveat
of photo bleaching in live cell conditions. Since the handle
groups will not react intracellularly, this is a clean method
to probe for inhibitors of enzyme active sites. The novelty
in this approach in vivo is the ability to visualize whether an
inhibitor is working in a small animal model. Mechanistic
studies have conﬁrmed that these probes can distinguish
active enzyme from their zymogen or inhibitor-bound forms
[128].
T h e r eh a v eb e e nm a n ya t t e m p t st od i s c o v e rc a n c e r -
relevant enzymes and new enzyme inhibitors by using ABPP
platforms. For example, using ABPs for the analysis of
cysteine proteases, Joyce and colleagues found that cysteine
cathepsin proteases are upregulated in HPV-induced cervical
carcinomas[119]. Rol´ enetal.usedthisstrategytoproﬁlethe
activities of individual ubiquitin-speciﬁc proteases (USPs) in
biopsies of HPV carrying cervical carcinoma and adjacent
normal tissue, and as a result, they discovered that ubiquitin-
carboxy hydrolase-L3 (UCHL3) and UCH37 are increased
in HPV-positive tumors [131], which encourages further
consideration of its use as therapeutic targets in cervical
cancer. Comparative ABPP analysis of an in-vivo-derived
variant of the human breast cancer cell line MDA-MB-
231, termed 231MFP, and parental MDA-MB-231 cells
revealed dramatic alterations in enzyme activities such as
upregulation of the serine proteases tissue-type (tPA) and
urokinase-type (uPA)plasminogen activatorsin the231MFP
cell line [132], highlighting the importance of an ABPP
for identifying and characterizing the protein signatures.
Wright and colleagues demonstrated the potential clinical
use of ABPs in drug discovery for cancer-related enzymes.
They used cytochrome-p450s- (CYP450s-) directed ABPs to
proﬁletheeﬀectsofCYP450activityonaromataseinhibitors,
which are used in breast cancer treatment. This led to the
identiﬁcation of the aromatase inhibitor, anastrozole, as an
inducer of CYP1A2 activity in breast cancer [117]. Based on
these ﬁndings, the technique appears to be exceptional for
cancer research given the aberrant functions many of these
enzyme classes have in cancer.
In recent years, ABPP has been combined with mass-
spectrometry-basedplatformssuchastandemMSandliquid
chromatography MS (LC/MS) to achieve great coverage
of the proteome [133–135]. For example, the integration
of ABPP with a liquid chromatography- (LC-) MS-based
platform, termed Multidimensional Protein Identiﬁcation
Technology (MudPIT), identiﬁed many enzyme activities
in breast cancer samples, and especially three enzymes
were signiﬁcantly upregulated in ER-/PR- breast cancers
compared to either ER+/PR+ or normal tissues [136]: (i)
KIAA1363, a serine hydrolase that is elevated in aggressive
breast and ovarian cancers [137]; (ii) ﬁbroblast activation
protein (FAP/Seprase), a cell-surface serine protease, pro-
moting growths of breast cancer in part, through enhanced
angiogenesis [138]; and (iii) platelet-activating factor acetyl-
hydrolase 2 (PAF-AH2), a lipase that degrades the endoge-
nous signaling molecule PAF [136, 139]. Therefore, the com-
bination of ABPP and mass-spectrometry-based proteomic
proﬁling may provide systematic and comprehensive infor-
mation for target identiﬁcation, target validation, and drug
discovery and allow the integration of individual enzyme
activities into the larger metabolic networks of cancer
cells.10 International Journal of Proteomics
16.Reverse Phase ProteinArray(RPPA)
Posttranslational modiﬁcation plays a pivotal role in cellular
signaling pathways, and one prominent biochemical role is
played by phosphorylation, indicating the need for technolo-
gies capable of detecting dynamic cellular changes in the
proteome. Although Western blotting has been a laboratory
staple for decades and is capable of detecting protein
phosphorylation, the limitations of this technique preclude
its incorporation into a clinical diagnostic setting for exam-
ining patient specimens. Thus, the high-throughput, novel,
proteomic approach reverse phase protein array (RPPA) was
developed to quantify signaling pathway activation using
protein phosphorylation-speciﬁc antibodies among a large
number of biological specimens, and RPPA was validated
[140–142]. The format allows measurement of protein
expression levels using antibodies on multiple biological
samples simultaneously in a quantitative manner.
Many studies have shown the ability of RPPA to simul-
taneously monitor multiple signaling pathways, allowing
rapid screening of potential molecular tumor markers and
targets [143, 144]. Dr. Gordon B. Mills and his group have
applied RPPA technique to proﬁle and validate key signal-
ing networks dysregulated in women’s cancers, including
ovarian and breast cancer, and these studies provide novel
insights into the diverse cell signaling-based mechanisms
underlying cancer progression [145–149]. Bartholomeusz
and colleagues used RPPAs to measure PEA-15 (also called
PED), which is believed to be a novel regulator of the
ERK/MAP kinase pathway, in 320 human breast cancers and
discovered that low expression of PEA-15 is correlated with
high nuclear grade and negative hormone receptor status
[150], suggesting its therapeutic potential as a druggable
target in breast cancer.
The antibody-based proteomics technique is a powerful
approach to functionally explore the human proteome
using speciﬁc antibodies and thus enable the generation
of a comprehensive proteomic network [151]. The major
advantage of RPPA is that it requires only miniscule sample
volume for protein detection, some suggesting that ∼20
cells provide a suﬃcient amount [152–154]. Therefore, very
limited amounts of sample, such as from a biopsy, could also
be analyzed for biomarker discovery and/or other clinical
diagnostics using this method.
Another major advantage of RPPA is that it can be used
for monitoring the protein dynamics over time. The whole-
cell lysates are immobilized in individual spots on an array
platform in a serial dilution curve, and then each array can
be probed with a speciﬁc antibody that can be detected
by chemiluminescence, ﬂuorescence, or colorimetric assays.
The array slide is scanned, and using the image, the visual
spots are quantiﬁed using specialized software designed for
this purpose. Multiplexing is carried out by probing multiple
protein arrays spotted with the same lysate and using
diﬀerent antibodies [155]. So far, RPPA has shown great
potential for clinical application; however, the variability and
comparability of staining between arrays represents a major
challenge to solve. Another disadvantage of using RPPA is
that it requires very-high-quality antibodies that have been
validated through traditional immunoblotting, which is a
time-consuming bottleneck for this assay.
17. ELISAandMultiplex Assay
Although the enzyme-linked immunosorbent assay (ELISA)
is a “gold standard” for protein detection in biological sam-
ples, it is quickly being updated and replaced by improved
techniques. The ELISA technique has been used in laborato-
ries for some time, even appearing in greatly dated biological
textbooks,makingitwellunderstoodandutilizedbymanyas
a complement or substitute for Western blotting. Although
ELISA is reliable, quantitative, and accurate, classical ELISA
uses a single antigen detection method and often requires
a relatively large volume of a biological sample, which may
make repeat testing diﬃcult. Furthermore, it is not often
the case that large sample amounts are available, partic-
ularly when replicates are necessary for accuracy. Even if
replicates are possible, a measurement from a heterogeneous
population of cells may be obscured using this method if
a subpopulation dominates the protein pool. Nevertheless,
its historical nature ensures that many of the biological tests
performed in diagnostic labs today are using ELISA. For
example, there are many diﬀerent types of ELISA test kits
commercially available for cervical cancer screening such
as Cervatec ELISA kit to detect p16INK4A and human HPV
ELISA kits to detect IgG or IgM.
Multiplex assays have been developed to overcome
challenges encountered in the classical ELISA, such as large
sample volume format, extensive time requirement, labor-
intensity, and the issue of quantifying multiple antigens
in a single sample [151]. The quality of the antibody
and its speciﬁcity for the target antigen remain a crucial
determinant in these assays and can frustrate even the most
well-intentioned scientists with otherwise infallible logic
and perfectly designed epitopes. Currently, ﬂow cytometry-
, chemiluminescence-, and electrochemiluminescence-based
multiplex assays are commercially available [156]. Flow
cytometry multiplex arrays (also known as bead-based mul-
tiplex assays) are currently a commonly used format. Each
beadset is coatedwithaspeciﬁccaptureantibody forasingle
antigen, and ﬂuorescence or streptavidin-labeled antibodies
bind to the speciﬁc capture antibody complex on the bead
set, which can be detected by ﬂow cytometry. The cytometric
bead array (CBA) system (BD Biosciences), the Luminex
multianalyte proﬁling (xMAP) technology (Luminex), and
MultiBead multiplex assay (Enzo Life Science) provides a
ﬂow cytometry-based multiplex assay.
Multiplex arrays have several advantages that improve
upon the challenges with ELISA, in particular that they
require far less sample volume per antigen, can be completed
withinashortertime,aremorecosteﬃcientperantigen,and
have the ability to reliably detect diﬀerent proteins across a
broaddynamicrangeofconcentrations[151,156].Multiplex
ELISA (Quansys Biosciences) and Proteome Proﬁler Arrays
(R&D Systems) provide a 96-well microplate coated with
multiple, speciﬁc capture antibodies, followed by chemilu-
minescent detection. MSD Multi-Array (Meso Scale Dis-
covery) employs electrochemiluminescence technology forInternational Journal of Proteomics 11
detection. They array the capture antibody on a microplate
with electrodes integrated into the bottom of the plate,
followed by detection with an electrochemiluminescent tag.
Studies examining the eﬀect of the PI3K inhibitor LY294002
on human xenografts demonstrated the multiplex assays’
eﬀectiveness and reliability to measure pharmacodynamic
responses [157]. Through these breakthrough technologies
and applications, multiplex assays for the detection of
biomarkers are becoming popular in preclinical and clinical
diagnostic research.
18. TissueMicroarrayandAutomated
QuantitativeAssessment of
Immunoﬂuorescence (TMA-AQUA)
Cancer biomarker studies using the combination of tis-
sue microarray and automated quantitative assessment of
immunoﬂuorescence (TMA-AQUA) have been successfully
applied for various types of human cancer [158]. TMA is a
high-throughput pathology platform for molecular proﬁling
of tumor specimens, principally using immunohistochem-
istry method [159], and has become a powerful tool for
cancer biomarker discovery over the past decade [160, 161].
Identifying and scoring cancer markers help researchers to
characterizethetumorandpredictdiseaseprogression,how-
ever, the current method for immunohistochemistry scoring
is labor-intensive, has inherent limitations to quantiﬁcation
and has the potential to introduce bias into the results
[162]. Therefore, the need for improvement of the quality,
reproducibility, and accuracy of immunohistochemistry is
obvious. Various automated image analysis software are
currently available, and several groups have demonstrated
that automated IHC scoring systems oﬀer time eﬃciency,
betteraccuracy,goodreproducibility,andhigherqualitydata
compared to manual analysis [163–166].
The HistoRx AQUA platform, a well-established, auto-
mated, ﬂuorescence-based immunohistochemistry image
analysis, identiﬁes tumor cells using tumor-speciﬁc proteins
such as cytokeratin. Doing this creates an interest region
and allows the quantitative assessment of protein expression
in formalin-ﬁxed paraﬃn-embedded tissue samples [167].
The output of the analysis (called the “AQUA score”) can be
correlated with other parameters such as disease detection,
progression, or response to therapy. The AQUA system
allows for high-throughput and high-resolution analysis of
TMA, therefore, the TMA-AQUA can serve as an eﬀec-
tive discovery tool and will help to advance personalized
medicine by identifying and validating new biomarker and
drug targets.
Several studies demonstrated that AQUA is capable of
measuring protein expression on histological specimens
obtained from various types of tumor with good accuracy
and reproducibility, possibly leading to better clinical out-
comes [168–171]. Aitken and colleagues used TMA-AQUA
platform for quantitative analysis of changes in ER, PR, and
Her2 expression in invasive primary breast carcinomas and
paired lymph nodes and demonstrated that this new method
could be a more accurate measurement for conferring
optimal beneﬁts to adjuvant therapy [172]. Harigopal and
colleagues used this method to investigate the prognostic
signiﬁcance of AIB1, TIF2, and NCoR protein expression
in breast cancer. As a result, high expression of AIB1 was
strongly correlated with poor patient survival, suggesting its
potential use as a prognostic and predictive marker in breast
cancer [173].
19. Summary
Large-scale genomic studies, such as the Cancer Genome
Atlas (TCGA) project funded by the National Human
Genome Research Institute (NHGRI) and the National
Cancer Institute (NCI), are identifying numerous cancer
susceptibility genes and proﬁling gene expression and have
made great strides in highlighting the molecular basis of
cancer. Although transcriptome and genome studies are
certainly worthwhile, these cannot alone capture the view of
cancer dynamics, without the incorporation of proteomics.
The advancement of proteomic technologies has ushered in
a new paradigm for highly integrative cancer research in
many ways, and the integration with other “OMICS” tech-
nologies now provides complementary information to better
understand the genetic nature of cancer. New and emerging
proteomics technologies are very promising and now readily
feasible for clinical applications including the identiﬁcation
of novel biomarkers, monitoring therapy response, and
disease progression, delivering on the great promise of
personalized cancer medicine. Although proteomics still
have challenges that need to be overcome, these approaches
will catalyze the development of platforms for personalized
medicine.
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